{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:21:16Z","timestamp":1767896476059,"version":"3.49.0"},"reference-count":31,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJCC"],"published-print":{"date-parts":[[2022,1,7]]},"DOI":"10.12998\/wjcc.v10.i1.260","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T03:12:01Z","timestamp":1640833921000},"page":"260-267","source":"Crossref","is-referenced-by-count":3,"title":["HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review"],"prefix":"10.12998","volume":"10","author":[{"given":"Luo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ye","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21583"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.552"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2017.06.004"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.07.013"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-014-0528-0"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.12.041"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1718"},{"key":"B8","unstructured":"Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5: 1001-1006"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14111-3"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2012.12.001"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.09.006"},{"key":"B12","unstructured":"Tural D, Karaca M, Zirtiloglu A, M Hacioglu B, Sendur MA, Ozet A. Receptor discordances after neoadjuvant chemotherapy and their effects on survival. J BUON 2019; 24: 20-25"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05421-7"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605360"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz012"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013554"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1332-7"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6608-1"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24762"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.019"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv611"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.006"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.262"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5050"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3292"},{"key":"B26","unstructured":"Tan QX, Qin QH, Yang WP, Lian B, Wei CY. Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. Int J Clin Exp Pathol 2014; 7: 4086-4094"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2013.08.012"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.09.002"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2013.16.4.395"},{"key":"B30","unstructured":"Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. J BUON 2013; 18: 366-371"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-010-0238-1"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i1\/260.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T03:14:13Z","timestamp":1640834053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i1\/260.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":31,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v10.i1.260","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,7]]}}}